# A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04996121/  
OnCo record `nct04996121` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XZP-5955 tablets in non-small-cell lung cancer, run by Xuanzhu Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04996121 by Xuanzhu Biopharmaceutical Co., Ltd., with 360 participants planned, started 2021-12-06 and due to reach its primary completion in 2025-09. Interventions recorded: XZP-5955 tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04996121
- Phase: 1/2
- Setting: The Safety Tolerability Pharmacokinetic Characteristics and Efficacy of XZP-5955 Tablets in Patients With NTRK or ROS1 Gene Fusion Locally Advanced or Metastatic Solid Tumors in a Single-arm Open-label Multi-center Phase I/II Clinical Study
- Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT04996121: https://clinicaltrials.gov/study/NCT04996121

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Xuanzhu Biopharmaceutical](https://onco.cc/companies/xuanzhu-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct04996121.json